View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 10, 2021updated 07 Jan 2022 5:42am

Aerogen and CanSinoBIO to partner for inhaled delivery of Covid-19 vaccine

In Phase III trials, Convidecia demonstrated 95.47% efficacy in preventing severe Covid-19 after administering a single dose.

CanSinoBIO has signed a development and commercial supply collaboration with Ireland based company Aerogen for the inhaled recombinant Covid-19 vaccine, Convidecia.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Under the partnership, the aerosolised vaccine will use Aerogen’s vibrating mesh aerosol technology for delivery.

The companies have not divulged the financial details of the collaboration.

Convidecia is intended to be directly inhaled through a cup dispenser into the airway of the individual.

This route imitates the SARS-CoV-2 virus’ natural infection pathway and could offer further benefits by inducing mucosal immunity.

According to interim data from CanSinoBIO’s Phase III clinical trials, the vaccine showed a 95.47% efficacy in severe Covid-19 prevention 14 days following administration of a single dose.

As vaccination through the inhaled aerosol route needs a significantly reduced vaccine volume, it offers the capability to inoculate a greater number of individuals in a cost-efficient manner than injectable vaccines.

Aerogen CEO and founder John Power said: “The world has an urgent need for an effective, low cost, globally scalable and globally accessible solution to mass vaccination.

“The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with a capacity to vaccinate in the billions.”

CanSinoBio is planning a commercial authorisation application in China.

The company is preparing further clinical trials for other countries.

CanSinoBIO chairman and CEO Dr Xuefeng YU said: “Our partnership with Aerogen started in 2013 and for almost a decade, we’ve been advancing the possibility of aerosol drug delivery.

“It is demonstrated that the aerosolised vaccine can stimulate mucosal immunity and significantly reduce the risk of transmission, which could be a solution to rapidly build mass immune protection and accelerate the end of the pandemic.”

In April, the company announced plans to start trials of its inhaled Covid-19 vaccine.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology